



# The association between immunosuppressants and outcomes of COVID-19

Chi-Kuei Hsu<sup>1</sup> and Chih-Cheng Lai <sup>2</sup>

<sup>1</sup>Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan. <sup>2</sup>Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.

Corresponding author: Chih-Cheng Lai ([dtmed141@gmail.com](mailto:dtmed141@gmail.com))



Shareable abstract (@ERSpublications)

**Immunosuppressants and underlying diseases could affect the outcome of patients of COVID-19, and this requires further analysis** <https://bit.ly/3A6rSeJ>

**Cite this article as:** Hsu C-K, Lai C-C. The association between immunosuppressants and outcomes of COVID-19. *Eur Respir J* 2022; 60: 2200816 [DOI: 10.1183/13993003.00816-2022].

This single-page version can be shared freely online.

Copyright ©The authors 2022. For reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 19 April 2022  
Accepted: 18 June 2022

*To the Editor:*

We read with great interest the study investigating the association between immunosuppressant and the outcome of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk (aRR) 1.56, 95% CI 1.10–2.22) which was mainly driven by exposure to systemic glucocorticoids (aRR 2.38, 95% CI 1.72–3.30). Overall, it is a well-designed study; however, we have three concerns about the findings of this study.